Molbio Diagnostics Ltd (MOLBIO) — Announcement | 5 September 2026

· BSE Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings
📢 Key Event
Board approves unaudited Q1 FY2026 financial results
💡 Investor Takeaway
Shareholders received formal confirmation of quarterly results and new materiality disclosure protocols.

Molbio Diagnostics announced approval of unaudited standalone and consolidated financial results for Q1 FY2026 ending June 30, 2026, following a board meeting on September 5, 2026. The filing also details authorization for key managerial personnel to assess material events and includes contact details for investor queries.

📄 View Original Announcement (PDF)

About Molbio Diagnostics Ltd (MOLBIO)

Healthcare · Healthcare · Listed on BSE

Market Cap: ₹16,255.48 Cr

View full MOLBIO stock details →

📡 Get AI alerts when MOLBIO files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track MOLBIO — Free

📊 More MOLBIO filings

See all MOLBIO filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when MOLBIO files new disclosures

Track MOLBIO filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track MOLBIO — Free

Free account · 2 AI queries/day